Finally, in terms of pharmaceutical products, I think it's almost certain that the intellectual property changes we've made to CETA will inevitably increase drug costs, which are often a cost driver for employers, particularly those that have drug plans for their employees. Do you have any concerns among your members—you represent the manufacturers and exporters—about increases to their drug plans costed in business? Has anybody expressed that to you?
On November 26th, 2013. See this statement in context.